Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non-Small-Cell Lung Cancer [Rapid Communication]
Conclusion
In this retrospective analysis, patients positive for T790M in plasma have outcomes with osimertinib that are equivalent to patients positive by a tissue-based assay. This study suggests that, upon availability of validated plasma T790M assays, some patients could avoid a tumor biopsy for T790M genotyping. As a result of the 30% false-negative rate of plasma genotyping, those with T790M-negative plasma results still need a tumor biopsy to determine presence or absence of T790M.
Source: Journal of Clinical Oncology - Category: Cancer & Oncology Authors: Oxnard, Thress, Alden, Lawrance, Paweletz, Cantarini, Yang, Barrett, Janne Tags: Rapid Communications, Translational Oncology Source Type: research
More News: Cancer | Cancer & Oncology | Laboratory Medicine | Legislation | Lung Cancer | Non-Small Cell Lung Cancer | Study